Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Digestive System Diseases

Skin and Connective Tissue Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Hepatocellular

Melanoma

Carcinoma, Renal Cell

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

Antineoplastic Agents

All Drugs and Chemicals

Immune Checkpoint Inhibitors

INCB086550 will be administered orally twice a day.

INCB086550

An open-label, nonrandomized study to evaluate the efficacy and safety of INCB086550, a first-in-class oral inhibitor of PD-L1, as initial immune checkpoint inhibitor therapy in participants with select solid tumors

Study of INCB086550 in Select Solid Tumors

A Phase 2 Study of INCB086550 (Oral PD-L1 Inhibitor) in Participants Who Are Immune Checkpoint Inhibitor-Naïve With Selected Solid Tumors

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Defined as the percentage of participants with a best overall response of CR or PR confirmed by at least 1 repeat assessment ≥ 28 days later according to RECIST v1.1 as determined by the investigator.

Defined as the percentage of participants with a best overall response of CR or PR confirmed by at least 1 repeat assessment ≥ 28 days later, or SD for ≥ 12 weeks, by investigator assessment per RECIST v1.1.

Defined as the time from the earliest date of CR or PR confirmed by at least 1 repeat assessment ≥ 28 days later until the earliest date of disease progression by investigator assessment per RECIST v1.1, or death due to any cause, if occurring sooner than progression

TEAE defined as any adverse event either reported for the first time or worsening of a pre-existing event after first dose of study treatment.

Incyte Corporation

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of INCB086550 in Select Solid Tumors	NCT04629339	Non Small Cell ... Urothelial Canc... Renal Cell Carc... Hepatocellular ... Melanoma	INCB086550	18 Years -	Incyte Corporation
Study of INCB086550 in Select Solid Tumors	NCT04629339	Non Small Cell ... Urothelial Canc... Renal Cell Carc... Hepatocellular ... Melanoma	INCB086550	18 Years -	Incyte Corporation
Study of INCB086550 in Select Solid Tumors	NCT04629339	Non Small Cell ... Urothelial Canc... Renal Cell Carc... Hepatocellular ... Melanoma	INCB086550	18 Years -	Incyte Corporation

Spots Global Cancer Trial Database for checkpoint inhibitor naive